Distinguished in Lung Metastases

Suresh Senan

Amsterdam, NH, NL 
Distinguished in Lung Metastases
Amsterdam, NH, NL 
OverviewLocationsClinical Research

Overview

Suresh Senan practices in Amsterdam, Netherlands. Mr. Senan is rated as a Distinguished expert by MediFind in the treatment of Lung Metastases. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Cardiac Ablation, and Endoscopy.

His clinical research consists of co-authoring 288 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 9 articles in the study of Lung Metastases.

Gender
Male

Locations

Amsterdam, NH, Netherlands
Other Locations
Noord, NB, Netherlands
Netherlands
Rijnstate Ziekenhuis
Arnhem, GE, Netherlands
Rotterdam, ZH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2025
Intervention Type: Other, Drug
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 3
A Randomized Clinical Trial of Surgery Versus Radiosurgery (Stereotactic Radiotherapy) in Patients With Stage IA NSCLC Who Are Fit to Undergo Primary Resection
A Randomized Clinical Trial of Surgery Versus Radiosurgery (Stereotactic Radiotherapy) in Patients With Stage IA NSCLC Who Are Fit to Undergo Primary Resection
Enrollment Status: Terminated
Publish Date: March 17, 2022
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
View 1 Less Clinical Trial

288 Total Publications

Beneficial value of [18F]FDG PET/CT in the follow-up of patients with stage III non-small cell lung cancer (NVALT31-PET study): study protocol of a multicentre randomised controlled trial.
Beneficial value of [18F]FDG PET/CT in the follow-up of patients with stage III non-small cell lung cancer (NVALT31-PET study): study protocol of a multicentre randomised controlled trial.
Journal: BMJ open
Published: July 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Senan's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile